Parkinson's disease (PD) is a common disorder of middle-aged and elderly people in which degeneration of the extrapyramidal motor system causes significant movement problems. In some patients, however, there are additional disturbances in sensory systems including loss of the sense of smell and auditory and/or visual problems. This paper is a general overview of the visual problems likely to be encountered in PD. Changes in vision in PD may result from alterations in visual acuity, contrast sensitivity, colour discrimination, pupil reactivity, eye movements, motion perception, visual field sensitivity, and visual processing speeds. Slower visual processing speeds can also lead to a decline in visual perception especially for rapidly changing visual stimuli. In addition, there may be disturbances of visuospatial orientation, facial recognition problems, and chronic visual hallucinations. Some of the treatments used in PD may also have adverse ocular reactions. The pattern electroretinogram (PERG) is useful in evaluating retinal dopamine mechanisms and in monitoring dopamine therapies in PD. If visual problems are present, they can have an important effect on the quality of life of the patient, which can be improved by accurate diagnosis and where possible, correction of such defects. 1. Introduction Parkinson's disease (PD) is a common neurodegenerative disorder affecting middle aged and elderly people. It is a disease characterised by deficiency of dopamine in areas of the midbrain causing a variety of movement problems such as akinesia, rigidity, and tremor. Despite the emphasis on motor function in PD, nonmotor symptoms may also play a significant role in determining the general quality of life of the patient. Hence, the symptoms of PD can include depression, apathy, sleep problems, cognitive impairment, dementia, and autonomic, gastrointestinal, and sensory problems [1]. Sensory problems may include visual loss, loss of smell, auditory problems, and “restless legs” syndrome (RLS). Visual signs and symptoms of PD may include defects in eye movement, pupillary function, and in more complex visual tasks involving the ability to judge distance or the shape of an object [2, 3]. The symptoms of PD can be treated successfully using drug therapy or surgery, and these treatments may also have visual side effects. Hence, this paper provides a general overview of (1) the visual signs and symptoms of PD, (2) the areas of the eye and brain which may be affected by the pathology of PD, and (3) the adverse ocular reactions to treatment. 2. Visual Symptoms in
References
[1]
A. Antal, F. Bandini, S. Kéri, and I. Bodis-Wollner, “Visuo-cognitive dysfunctions in Parkinson's disease,” Clinical Neuroscience, vol. 5, supplement 2, pp. 147–152, 1998.
[2]
R. A. Armstrong, “Parkinson's disease and the eye,” Ophthalmic and Physiological Optics, vol. 17, no. 2, pp. S9–S16, 1997.
[3]
R. A. Armstrong, “Visual signs and symptoms of Parkinson's disease,” Clinical and Experimental Optometry, vol. 91, no. 2, pp. 129–138, 2008.
[4]
M. X. Repka, M. C. Claro, D. N. Loupe, and S. G. Reich, “Ocular motility in Parkinson's disease,” Journal of Pediatric Ophthalmology and Strabismus, vol. 33, no. 3, pp. 144–147, 1996.
[5]
R. D. Jones and I. M. Donaldson, “Fractionation of visuoperceptual dysfunction in Parkinson's disease,” Journal of the Neurological Sciences, vol. 131, no. 1, pp. 43–50, 1995.
[6]
R. D. Jones, I. M. Donaldson, and P. L. Timmings, “Impairment of high-contrast visual acuity in Parkinson's disease,” Movement Disorders, vol. 7, no. 3, pp. 232–238, 1992.
[7]
H. Matsui, F. Udaka, A. Tamura et al., “Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease,” Journal of Geriatric Psychiatry and Neurology, vol. 19, no. 1, pp. 36–40, 2006.
[8]
M. J. Price, R. G. Feldman, D. Adelberg, and H. Kayne, “Abnormalities in color vision and contrast sensitivity in Parkinson's disease,” Neurology, vol. 42, no. 4, pp. 887–890, 1992.
[9]
T. Buttner, W. Kuhn, P. Klotz et al., “Disturbance of colour perception in Parkinson's disease,” Journal of Neural Transmission, vol. 6, no. 1, pp. 11–15, 1993.
[10]
N. J. Diederich, R. Raman, S. Leurgans, and C. G. Goetz, “Progressive worsening of spatial and chromatic processing deficits in Parkinson disease,” Archives of Neurology, vol. 59, no. 8, pp. 1249–1252, 2002.
[11]
O. Veselá, E. R？？i？ka, R. Jech et al., “Colour discrimination impairment is not a reliable early marker of Parkinson's disease,” Journal of Neurology, vol. 248, no. 11, pp. 975–978, 2001.
[12]
S. Ture, I. Inci, and M. Gedizlioglu, “Abnormalities of contrast sensitivity, visual fields and visual evoked potentials in Parkinson’s disease and effect of dopaminergic treatment,” Journal of Neurology, vol. 254, supplement 3, p. 93, 2007.
[13]
A. U. Bayer, O. N. Keller, F. Ferrari, and K. P. Maag, “Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease,” American Journal of Ophthalmology, vol. 133, no. 1, pp. 135–137, 2002.
[14]
V. Biousse, N. J. Newman, C. Carroll et al., “Visual fields in patients with posterior GPi pallidotomy,” Neurology, vol. 50, no. 1, pp. 258–265, 1998.
[15]
H. Shibasaki, S. Tsuji, and Y. Kuroiwa, “Oculomotor abnormalities in Parkinson's disease,” Archives of Neurology, vol. 36, no. 6, pp. 360–364, 1979.
[16]
T. Crawford, S. Goodrich, L. Henderson, and C. Kennard, “Predictive responses in Parkinson's disease: manual keypresses and saccadic eye movements to regular stimulus events,” Journal of Neurology Neurosurgery and Psychiatry, vol. 52, no. 9, pp. 1033–1042, 1989.
[17]
C. Winograd-Gurvich, N. Georgiou-Karistianis, P. B. Fitzgerald, L. Millist, and O. B. White, “Self-paced saccades and saccades to oddball targets in Parkinson's disease,” Brain Research, vol. 1106, no. 1, pp. 134–141, 2006.
[18]
S. Shaunak, E. O'Sullivan, S. Blunt et al., “Remembered saccades with variable delay in Parkinson's disease,” Movement Disorders, vol. 14, no. 1, pp. 80–86, 1999.
[19]
T. L. Hodgson, W. H. Dittrich, L. Henderson, and C. Kennard, “Eye movements and spatial working memory in Parkinson's disease,” Neuropsychologia, vol. 37, no. 8, pp. 927–938, 1999.
[20]
M. Bares, M. Brazdil, P. Kanovsky, et al., “The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinson’s disease,” Parkinsonism & Related Disorders, vol. 9, pp. 139–144, 2003.
[21]
M. S. Corin, T. S. Elizan, and M. B. Bender, “Oculomotor function in patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 15, no. 3, pp. 251–265, 1972.
[22]
F. E. Lepore, “Parkinson's disease and diplopia,” Neuro-Ophthalmology, vol. 30, no. 2-3, pp. 37–40, 2006.
[23]
V. Biousse, B. C. Skibell, R. L. Watts, D. N. Loupe, C. Drews-Botsch, and N. J. Newman, “Ophthalmologic features of Parkinson's disease,” Neurology, vol. 62, no. 2, pp. 177–180, 2004.
[24]
H. G. Garland, “Refresher course for general practitioners. Parkinsonism,” British Medical Journal, vol. 1, pp. 153–155, 1952.
[25]
K. R. Peshori, E. J. Schicatano, R. Gopalaswamy, E. Sahay, and C. Evinger, “Aging of the trigeminal blink system,” Experimental Brain Research, vol. 136, no. 1, pp. 351–363, 2001.
[26]
G. Micieli, C. Tassorelli, E. Martignoni et al., “Disordered pupil reactivity in Parkinson's disease,” Clinical Autonomic Research, vol. 1, no. 1, pp. 55–58, 1991.
[27]
C. Bulens, J. D. Meerwaldt, G. J. Van Der Wildt, and J. B. P. Van Deursen, “Effect of levodopa treatment on contrast sensitivity in Parkinson's disease,” Annals of Neurology, vol. 22, no. 3, pp. 365–369, 1987.
[28]
J. T. Hutton, J. L. Morris, and J. W. Elias, “Levodopa improves spatial contrast sensitivity in Parkinson's disease,” Archives of Neurology, vol. 50, no. 7, pp. 721–724, 1993.
[29]
I. Bodis-Wollner, M. S. Marx, S. Mitra, P. Bobak, L. Mylin, and M. Yahr, “Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity,” Brain, vol. 110, no. 6, pp. 1675–1698, 1987.
[30]
R. L. Rodnitzky, “Visual dysfunction in Parkinson's disease,” Clinical Neuroscience, vol. 5, no. 2, pp. 102–106, 1998.
[31]
T. H. Büttner, T. H. Müller, and W. Kuhn, “Effects of apomorphine on visual functions in Parkinson's disease,” Journal of Neural Transmission, vol. 107, no. 1, pp. 87–94, 2000.
[32]
D. Guehl, P. Burbaud, C. Lorenzi et al., “Auditory temporal processing in Parkinson's disease,” Neuropsychologia, vol. 46, no. 9, pp. 2326–2335, 2008.
[33]
D. L. Harrington, K. Y. Haaland, and N. Hermanowicz, “Temporal processing in the basal ganglia,” Neuropsychology, vol. 12, no. 1, pp. 3–12, 1998.
[34]
C. R. Jones and M. Jahanshahi, “The substantia nigra, the basal ganglia, dopamine and temporal processing,” Journal of Neural Transmission, no. 73, pp. 161–171, 2009.
[35]
I. Gottlob, E. Schneider, W. Heider, and W. Skrandies, “Alteration of visual evoked potentials and electroretinograms in Parkinson's disease,” Electroencephalography & Clinical Neurophysiology, vol. 66, pp. 349–357, 1987.
[36]
A. Peppe, P. Stanzione, F. Pierelli, D. De Angelis, M. Pierantozzi, and G. Bernardi, “Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials,” Neurology, vol. 45, pp. 1144–1148, 1995.
[37]
I. Bodis-Wollner and A. Tzelepi, “The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D and D receptor ligands on the pattern electroretinogram,” Vision Research, vol. 38, no. 10, pp. 1479–1487, 1998.
[38]
M. Tagliati, I. Bodis-Wollner, and M. D. Yahr, “The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning,” Electroencephalography and Clinical Neurophysiology, vol. 100, no. 1, pp. 1–11, 1996.
[39]
M. Tagliati, I. Bodis-Wollner, I. Kovanecz, and P. Stanzione, “Spatial frequency tuning of the monkey pattern ERG depends on D2 receptor-linked action of dopamine,” Vision Research, vol. 34, no. 16, pp. 2051–2057, 1994.
[40]
P. Stanzione, I. Bodis-Wollner, M. Pierantozzi et al., “A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations,” Clinical Neurophysiology, vol. 110, no. 1, pp. 82–85, 1999.
[41]
M. Li, Y. Kuroiwa, L. Wang et al., “Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson's disease: a visual event-related potentials study,” Parkinsonism and Related Disorders, vol. 9, no. 6, pp. 329–340, 2003.
[42]
L. Wang, Y. Kuroiwa, T. Kamitani et al., “Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson's disease,” Journal of Neurology, vol. 247, no. 5, pp. 356–363, 2000.
[43]
L. Barbato, S. Rinalduzzi, M. Laurenti, S. Ruggieri, and N. Accornero, “Color VEPs in Parkinson's disease,” Electroencephalography and Clinical Neurophysiology, vol. 92, no. 2, pp. 169–172, 1994.
[44]
F. Sartucci, G. Orlandi, U. Bonuccelli et al., “Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease,” Neurological Sciences, vol. 26, no. 6, pp. 395–401, 2006.
[45]
I. Bodis-Wollner and M. D. Yahr, “Measurements of visual evoked potentials in Parkinson's disease,” Brain, vol. 101, no. 4, pp. 661–671, 1978.
[46]
M. Onofrj and I. Bosid-Wollner, “Dopaminergic deficiency causes delayed visual evoked potentials in rats,” Annals of Neurology, vol. 11, no. 5, pp. 484–490, 1982.
[47]
I. Bodis-Wollner, M. D. Yahr, L. Mylin, and J. Thornton, “Dopaminergic deficiency and delayed visual evoked potentials in humans,” Annals of Neurology, vol. 11, no. 5, pp. 478–483, 1982.
[48]
B. E. Levin, M. M. Llabre, S. Reisman et al., “Visuospatial impairment in Parkinson's disease,” Neurology, vol. 41, no. 3, pp. 365–369, 1991.
[49]
S. Davidsdottir, A. Cronin-Golomb, and A. Lee, “Visual and spatial symptoms in Parkinson's disease,” Vision Research, vol. 45, no. 10, pp. 1285–1296, 2005.
[50]
G. L. Trick, B. Kaskie, and S. B. Steinman, “Visual impairment in Parkinson's disease: deficits in orientation and motion discrimination,” Optometry and Vision Science, vol. 71, no. 4, pp. 242–245, 1994.
[51]
P. J. Lang, “Presidential address, 1978. A bio-informational theory of emotional imagery,” Psychophysiology, vol. 16, no. 6, pp. 495–512, 1979.
[52]
R. Sprengelmeyer, A. W. Young, K. Mahn et al., “Facial expression recognition in people with medicated and unmedicated Parkinson's disease,” Neuropsychologia, vol. 41, no. 8, pp. 1047–1057, 2003.
[53]
T. L. Hodgson, B. Tiesman, A. M. Owen, and C. Kennard, “Abnormal gaze strategies during problem solving in Parkinson's disease,” Neuropsychologia, vol. 40, no. 4, pp. 411–422, 2002.
[54]
N. J. Diederich, C. G. Goetz, and G. T. Stebbins, “Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model,” Movement Disorders, vol. 20, no. 2, pp. 130–140, 2005.
[55]
G. Fénelon, F. Mahieux, R. Huon, and M. Ziégler, “Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors,” Brain, vol. 123, no. 4, pp. 733–745, 2000.
[56]
L. A. Hunt, A. A. Sadun, and C. J. Bassi, “Review of the visual system in Parkinson's disease,” Optometry and Vision Science, vol. 72, no. 2, pp. 92–99, 1995.
[57]
P. N. Patil and T. F. Mauger, “Cholinergic sensitivity of irides from donors with various pathological conditions and lens implants,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 346, no. 6, pp. 620–628, 1992.
[58]
J. E. Dowling, B. Ehinger, and W. L. Hedden, “The interplexiform cell: a new type of retinal neuron,” Investigative Ophthalmology, vol. 15, no. 11, pp. 916–926, 1976.
[59]
J. M. Frederick, M. E. Rayborn, and A. M. Laties, “Dopaminergic neurons in the human retina,” Journal of Comparative Neurology, vol. 210, no. 1, pp. 65–79, 1982.
[60]
G. Masson, D. Mestre, and O. Blin, “Dopaminergic modulation of visual sensitivity in man,” Fundamental and Clinical Pharmacology, vol. 7, no. 8, pp. 449–463, 1993.
[61]
M. B. A. Djamgoz, M. W. Hankins, J. Hirano, and S. N. Archer, “Neurobiology of retinal dopamine in relation to degenerative states of the tissue,” Vision Research, vol. 37, no. 24, pp. 3509–3529, 1997.
[62]
J. Nguyen-Legros, C. Harnois, T. Di Paolo, and A. Simon, “The retinal dopamine system in Parkinson's disease,” Clinical Vision Sciences, vol. 8, no. 1, pp. 1–12, 1993.
[63]
R. Inzelberg, J. A. Ramirez, P. Nisipeanu, and A. Ophir, “Retinal nerve fiber layer thinning in Parkinson disease,” Vision Research, vol. 44, no. 24, pp. 2793–2797, 2004.
[64]
R. A. Armstrong and A. B. Syed, “Alzheimer's disease and the eye,” Ophthalmic and Physiological Optics, vol. 16, no. 1, pp. S2–S8, 1996.
[65]
M. G. Spillantini, R. Anthony Crowther, R. Jakes, N. J. Cairns, P. L. Lantos, and M. Goedert, “Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies,” Neuroscience Letters, vol. 251, no. 3, pp. 205–208, 1998.
[66]
J. L. Eberling, B. C. Richardson, B. C. Reed, N. Wolfe, and W. J. Jagust, “Cortical glucose metabolism in Parkinson's disease without dementia,” Neurobiology of Aging, vol. 15, no. 3, pp. 329–335, 1994.
[67]
F. Baglio, V. Blasi, A. Falini et al., “Functional brain changes in early Parkinson's disease during motor response and motor inhibition,” Neurobiology of Aging, vol. 32, no. 1, pp. 115–124, 2009.
[68]
B. Rieger and H. J. Markowitsch, “Implicit and explicit mnestic performance of patients with prefrontal, medial temporal, and basal ganglia damage,” Neurology Psychiatry and Brain Research, vol. 4, no. 2, pp. 53–74, 1996.
[69]
M. A. Basso, J. J. Pokorny, and P. Liu, “Activity of substantia nigra pars reticulata neurons during smooth pursuit eye movements in monkeys,” European Journal of Neuroscience, vol. 22, no. 2, pp. 448–464, 2005.
[70]
R. J. Naylor, “The ocular effects of parkinsonism and its treatment,” Optometry in Practice, vol. 6, pp. 19–31, 2005.
[71]
Z. Friedman and E. Neumann, “Benzhexol-induced blindness in Parkinson's disease,” British Medical Journal, vol. 1, no. 800, p. 605, 1972.
[72]
A. S. Spiers, D. B. Calne, and P. M. Fayers, “Miosis during L-dopa therapy,” British Medical Journal, vol. 2, no. 7, pp. 639–640, 1970.
[73]
A. W. Michell, Z. Xu, D. Fritz et al., “Saccadic latency distributions in Parkinson's disease and the effects of L-dopa,” Experimental Brain Research, vol. 174, no. 1, pp. 7–18, 2006.
[74]
S. Peters, G. Schweibold, H. Przuntek, and T. Muller, “Loss of visual acuity under dopamine substitution therapy,” Neuro-Ophthalmology, vol. 24, no. 1, pp. 273–277, 2000.
[75]
J. T. Pearlman, A. H. Kadish, and J. C. Ramseyer, “Vision loss associated with amantadine hydrochloride use,” Journal of the American Medical Association, vol. 237, no. 12, p. 1200, 1977.
